A new study shows that the high-dose flu vaccine, usually given to seniors, is linked to a remarkable 20% decline in the risk of Alzheimer’s dementia. This adds to the body of evidence that vaccines reduce both Alzheimer’s disease and dementia.
We don’t know the precise reason why vaccines reduce the risk of these diseases, but it’s probably because they prevent the disease that may increase the risk of dementia. This is more evidence that seniors should opt for all the vaccines indicated for their ages, including the high-dose flu and shingles.
This post will examine this new study about the high-dose flu vaccine and the risk of Alzheimer’s dementia.

What are Alzheimer’s disease and dementia?
Before I proceed, it’s important to describe Alzheimer’s disease (AD). It is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It accounts for 60-70% of dementia cases, even though the terms are sometimes used interchangeably. Alzheimer’s disease is a form of dementia. All Alzheimer’s disease cases are dementia, but not all dementia is AD.
In Alzheimer’s disease, amyloid plaques, phosphorylated tau tangles, and neurofibrillary tangles are generally easily visible pathologies that can be observed by microscopic analysis of brain tissue from autopsies of deceased individuals. These plaques and tangles seem to affect nerve functioning. Despite these observations, the precise pathophysiology, or development, of the disease is unknown.
Since amyloid plaques are often identified in patients with Alzheimer’s disease, a large amount of research is focused on attacking those plaques as a way to reverse the effect on nerves, which leads to AD.
The causes of AD and dementia are unknown (note the significant gaps in our understanding of this disease). However, it is speculated that this relationship is largely genetically determined, with many genes underlying the disease.
Since we do not understand the etiology and pathophysiology of AD, few treatments are available today. Some drugs target the amyloid plaques but have not been shown to change the outcomes of AD.
A couple of medications help manage some of the AD’s symptoms, but they are certainly not cures, and they are very expensive. Several drugs at the earliest stages of development may hold out hope of treating the underlying disease, but we are years away from knowing if they work or not.
One more thing that needs to be made clear. There are no biological tests for Alzheimer’s disease — usually, you can only find the amyloid plaques and other pathologies in post-mortem autopsies. Unfortunately, in the absence of an autopsy, clinical diagnoses of AD are “possible” or “probable”, based on other findings, such as memory tests and other methods.

High-dose flu vaccine and Alzheimer’s dementia study
In a paper published on 28 April 2026 in Neurology, Avram S Bukhbinder, MD, Massachusetts General Hospital, Boston, and colleagues analyzed data from 2014 to 2019 from IQVIA PharMetrics Plus for Academics, a US healthcare claims database.
All standard-dose, nonadjuvanted, non-recombinant, inactivated flu vaccines approved in the US during the study period for people 50 and older were grouped as standard vaccines. The only high-dose flu vaccine was a more concentrated formulation that was approved in the US in 2009.
Eligible participants were 65 and older, with 2 or more years of continuous medical and prescription drug coverage and no prior indicators of cognitive impairment. The participants were followed for up to 3 years after vaccination. Incident Alzheimer’s dementia was defined through diagnostic codes or claims for one of four drugs used to treat Alzheimer’s symptoms: donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), or memantine (Namenda).
The high-dose group included 120,775 unique participants, and the standard-dose group included 44,022 after weighting. The mean age in both groups was 74 years, and 57% were women.
Here are the key results
- Per-protocol analyses indicated that the risk for Alzheimer’s dementia was reduced by 22% at month 1.
- The effect persisted for 25 months with a 11% reduction in risk.
- After sex stratification, risk reduction persisted longer among women.
The authors concluded:
This retrospective cohort study used a large US claims database to investigate whether AD risk differs between adults ≥65 years old who received a high-dose influenza vaccine compared with a standard-dose influenza vaccine over a follow-up period of up to 3 years. We found that the risk of incident AD was significantly lower after H-IIV (high-dose) compared with S-IIV (standard dose) for the first 25 months postvaccination, with a minimum NNT of 185.2 at month 25.
Summary
This study adds more evidence to the fact that vaccines, in this case the high-dose flu vaccine, in seniors help reduce the risk of developing Alzheimer’s disease or dementia.
Once again, these vaccines do not have a direct effect on AD or dementia (at least, as far as we know). They work by preventing infectious diseases that may increase the risk of AD or dementia. We need additional research to determine the mechanisms linking vaccines and reduced risks of Alzheimer’s disease and dementia.
Seniors should get the high-dose flu vaccine to prevent the flu, which can lead to serious complications for older individuals, including hospitalization and death.
Get the high-dose flu vaccine in time for the next flu season.
Citations
- Bukhbinder AS, Ling Y, Jhin L, He E, Harris K, Rodriguez M, Thomas J, Cruz G, Phelps K, Kim Y, Chen L, Jiang X, Schulz PE. Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination. Neurology. 2026 Apr 28;106(8):e214782. doi: 10.1212/WNL.0000000000214782. Epub 2026 Apr 1. PMID: 41921123; PMCID: PMC13051479.
Help the Skeptical Raptor keep writing about vaccines
There are four ways you can help contribute to keeping this website running at full speed:
- GoFundMe.
- Subscribing via Patreon.
- Buying your favorite stuff on Amazon.
- Sharing this article on Social Media.
Discover more from Skeptical Raptor
Subscribe to get the latest posts sent to your email.
